Daily Stock Analysis, INSY, INSYS Therapeutics Inc, priceseries

INSYS Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.00
Close
0.00
High
0.00
Low
0.00
Previous Close
0.00
Daily Price Gain
0.00
YTD High
0.00
YTD High Date
Wrong Month 0, 0
YTD Low
0.00
YTD Low Date
Wrong Month 0, 0
YTD Price Change
0.00
YTD Gain
-nan%
52 Week High
0.00
52 Week High Date
Wrong Month 0, 0
52 Week Low
0.00
52 Week Low Date
Wrong Month 0, 0
52 Week Price Change
0.00
52 Week Gain
-nan%
Company Information
Stock Symbol
INSY
Exchange
NasdaqGM
Company URL
http://www.insysrx.com
Company Phone
602-910-2617
CEO
Saeed Motahari
Headquarters
Arizona
Business Address
10220 SOUTH 51ST STREET, SUITE 2, PHOENIX, AZ 85044
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001516479
About

INSYS Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. INSYS Therapeutics was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Description

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.